Tempest Therapeutics, Inc.
NASDAQ:TPST
0.9411 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0.295 | 0.653 | 0.277 | 9.735 | 0 | 0 |
| Cost of Revenue
| 0.381 | 1.814 | 1.27 | 0.815 | 1.052 | 0.032 | 0.028 | 5.401 | 2.249 | 0 | 0 | 0 |
| Gross Profit
| -0.381 | -1.814 | -1.27 | -0.815 | -1.052 | -0.032 | 0.267 | -4.748 | -1.972 | 9.735 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.905 | -7.271 | -7.119 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 17.498 | 22.527 | 17.166 | 14.389 | 27.843 | 14.425 | 14.526 | 21.641 | 18.433 | 21.784 | 15.802 | 6.323 |
| General & Administrative Expenses
| 11.659 | 12.113 | 9.82 | 4.909 | 5.507 | 12.449 | 27.744 | 49.223 | 51.594 | 26.149 | 13.332 | 7.206 |
| Selling & Marketing Expenses
| -0.381 | 0 | 0 | 0 | 16.498 | -3.79 | -21.816 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.659 | 12.113 | 9.82 | 4.909 | 16.504 | 8.659 | 5.928 | 49.223 | 51.594 | 26.149 | 13.332 | 7.206 |
| Other Expenses
| 0 | 0.549 | -0.034 | 0 | 0 | 0 | 4.03 | 5.4 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 29.157 | 34.64 | 26.986 | 19.298 | 44.347 | 23.084 | 20.454 | 70.864 | 70.027 | 47.933 | 29.134 | 13.529 |
| Operating Income
| -29.157 | -34.64 | -26.986 | -19.298 | -45.399 | -23.116 | -20.482 | -75.612 | -71.999 | -47.933 | -29.134 | -13.529 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -69.431 | -115.792 | -259.924 | -4.924 | 0 | 0 |
| Total Other Income Expenses Net
| -0.334 | -1.069 | -1.316 | 0.09 | 0.831 | -4.061 | -64.104 | -6.447 | -1.145 | -1.587 | 0.09 | 0.019 |
| Income Before Tax
| -29.491 | -35.709 | -28.302 | -19.208 | -44.568 | -27.177 | -84.586 | -82.059 | -73.144 | -49.52 | -29.044 | -13.51 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -286.732 | -125.665 | -264.058 | -5.087 | 0 | 0 |
| Income Tax Expense
| 0 | 1.069 | 1.248 | -0.09 | 0.001 | -0.169 | 0.067 | 0.201 | 0.075 | -1.587 | 0.09 | 0 |
| Net Income
| -29.491 | -36.778 | -29.55 | -19.118 | -44.568 | -27.192 | -84.578 | -82.26 | -73.219 | -49.52 | -29.044 | -13.51 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -286.705 | -125.972 | -264.329 | -5.087 | 0 | 0 |
| EPS
| -1.91 | -3.18 | -7.8 | -612.56 | -48.77 | -263.65 | -72,406.33 | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 |
| EPS Diluted
| -1.91 | -3.18 | -7.8 | -612.56 | -48.77 | -263.65 | -72,406.33 | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 |
| EBITDA
| -28.776 | -34.091 | -26.646 | -18.959 | -44.347 | -23.084 | -20.454 | -73.374 | -70.713 | -49.07 | -28.813 | -13.529 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -69.336 | -112.364 | -255.282 | -5.041 | 0 | 0 |